17 results match your criteria: "University of Vermont Medical Centre[Affiliation]"
Electrodiagnostic subtyping in Guillain-Barré syndrome patients in the International Guillain-Barré Outcome Study.
Eur J Neurol
September 2024
Department of Neurology, Johns Hopkins University, Baltimore, Vermont, USA.
Background And Purpose: Various electrodiagnostic criteria have been developed in Guillain-Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from the International GBS Outcome Study (IGOS) cohort were used to compare two widely used criterion sets and relate these to diagnostic amyotrophic lateral sclerosis criteria.
View Article and Find Full Text PDFTo guide future practice, perinatal trials should be much larger, simpler and less fragile with close to 100% ascertainment of mortality and other key outcomes.
Semin Perinatol
August 2023
From the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia.
Article Synopsis
- The Australian Placental Transfusion Study looked at how long to wait before cutting the umbilical cord in babies, comparing waiting at least 60 seconds to waiting 10 seconds or less.
- The study found that waiting longer might help reduce the chances of babies dying or having disabilities by 17%.
- However, the results aren't super strong because a few missing data points could change things, so future studies should try to collect all important information to make the results more reliable.
CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.
Neurology
June 2023
From the Department of Neurology (H.A.-H., H.A., T.H.), Aarhus University Hospital, Denmark; Department of Neurology (A.Y.D., B.v.d.B., C.V., J.R., S.E.L., S. Arends, L.W.G.L., K.K., B.C.J.), Erasmus MC, University Medical Centre Rotterdam, the Netherlands; Department of Neurology (A.M.S.), University of Michigan School of Medicine, Ann Arbor; Department of Neurology (S.A.Z.), University of Pittsburgh Medical Center, PA; Department of Neurology (H.J.W., A.D.), College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom; Department of Neurology (D.R.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurology (K.C.G.), St. Elizabeth's Medical Centre, Tufts University, School of Medicine, Boston, MA; Laboratory of Gut-Brain Signaling (Z.I.); Laboratory Sciences and Services Division (LSSD) (Z.I.), icddr,b; National Institute of Neurosciences and Hospital (Q.D.M.), Dhaka, Bangladesh; Department of Neurology (S.H.S.), Odense University Hospital and University of Southern Denmark; Department of Neurology (S. Kusunoki), Kindai University Faculty of Medicine, Osaka-Sayama City, Japan; Department of Neurology (C.C.), Neuromuscular Unit, Bellvitge University Hospital-IDIBELL, CIBERER, Barcelona, Spain; Division of Neurology (K.B.), Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa; Department of Neurology (J.A.L.M.), Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom; Department of Neurology (B.v.d.B., H.K.), Franciscus Gasthuis & Vlietland (location: Vlietland Hospital), Schiedam; Department of Neurology (S. Arends, P.W.W.), Haga Hospital, Den Haag; Department of Neurology (L.W.G.L., L.H.V.), St. Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands; Department of Neurology (L.B.), IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Neurology (S. Kuwabara), Chiba University, Chuo-ku, Japan; Department of Neurology (P.V.d.B.), Neuromuscular Reference Centre, University Hospital Saint-Luc, University of Louvain, Brussels, Belgium; Department of Neurology (S.M.), Hospital de PediatrÃa J.P. Garrahan, Buenos Aires, Argentina; Dysimmune Neuropathies Unit (G.A.M.), Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy; Department of Medicine (N.S.), University of Malaya, Kuala Lumpur, Malaysia; Department of Neurology (G.G.), University Hospital of Modena, Italy; Department of Clinical Neurophysiology (Y.P.), Reference Centre for NMD, CHU Nantes, Nantes, France; Department of Neurology (J.B.), Saarland University Medical School, Homburg (previous hospital), and MVZ Pfalzklinikum (J.B.), Kusel, Germany (current hospital); Department of Neurology (K.K., R.P.K.), Albert Schweitzer Hospital, Dordrecht, the Netherlands; Department of Neurology (C.M.), Hospital Británico, Buenos Aires, Argentina; Department of Neurology (M.J.S.T.), Hospital Marques de Valdecilla, Santander; Department of Neurology (L.Q., L.M.-A.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERER and ERN-NMD, Spain; Department of Neurology (Y.W.), Affiliated Hospital of Jining Medical University, Shandong Province, China; Neuromuscular and Neuroimmunology Service (E.N.-O.), IRCCS Humanitas Research Hospital, Milan University, Italy; Nuffield Department of Clinical Neurosciences (S.R.), University of Oxford and Oxford University Hospitals NHS Foundation Trust, United Kingdom; Department of Neurosciences, Ophthalmology, Rehabilitation, Genetics and Maternal Sciences (A.S.), University of Genova, and IRCCS San Martino Hospital (A.S.), Genova, Italy; Department of Neurology (J.P.), Hospital ClÃnico de Santiago, Travesia Choupana, Santiago de Compostela (A Coruña), Spain; Department of Neurology (F.H.V.), Franciscus Gasthuis & Vlietland (location: Franciscus Gasthuis), Rotterdam, the Netherlands; Department of Neurology (W.W., N.K.), University of Vermont Medical Centre, Burlington; Department of Neurology (H.C.L.), University Hospital of Cologne, Germany; Department of Neurology (V.G., B.S.), Montefiore Medical Center, Bronx, NY; Department of Neurology (G.C.), University Milano-Bicocca, Monza, Italy; Department of Neurology (G.G.-G.), Hospital Universitario Infanta SofÃa, San Sebastián de los Reyes, Spain; Department of Neurology (F.A.B.), Instituto de Investigaciones Neurológicas Raúl Carrea, FLENI, Buenos Aires, Argentina; Department of Neurology (H.D.K.), University Health Network, University of Toronto, Ontario, Canada; Department of Neurology (E.D.), University Hospital of Larissa, Greece; Department of Neurology (S. Attarian), Reference Centre for NMD, CHU Timone ERN NMD, Marseille, France; Department of Neurology (A.J.v.d.K., F.E.), Amsterdam University Medical Centre, University of Amsterdam, Neuroscience Institute; Department of Neurology (J.P.A.S.), Maasstad Hospital, Rotterdam; Department of Neurology (H.J.G.), Reinier de Graaf Hospital, Reinier de Graafweg, Delft, the Netherlands; Department of Neurology (R.D.M.H.), King's College Hospital, Denmark Hill, London; Department of Neurology (J.K.L.H.), The Walton Centre, Liverpool, United Kingdom; Department of Neurology (K.A.S.), University of Texas Health Science Centre at Houston; Department of Biology (N.K., S. Karafiath), Utah Valley University, Orem; Department of Neurology (M.V.), Lahey Hospital and Medical Center, Tufts University School of Medicine, Burlington, MA; Department of Neurology, Mental Health and Sensory Organs (NESMOS) (G.A.), Faculty of Medicine and Psychology, University of Rome "Sapienza," Sant' Andrea Hospital, Italy; Department of Clinical Neurosciences (T.E.F.), University of Calgary, Alberta, Canada; Department of Neurology (C.F.), Maastricht University Medical Centre, the Netherlands; Department of Neurology (M.B.), Leeds Teaching Hospitals; Department of Neurology (R.C.R.), Addenbrooke's Hospital, Cambridge, United Kingdom; Department of Neurology (N.J.S.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY; Department of Neurology (R.F.), Scientific Institute San Raffaele, Milano, Italy; Department of Neurology (G.W.v.D.), Canisius Wilhelmina Hospital, Nijmegen; Department of Neurology (M.P.J.G.), Jeroen Bosch Hospital, 's-Hertogenbosch; Department of Neurology (J.V.), Leiden University Medical Centre; and Department of Immunology (B.C.J.), Erasmus MC, University Medical Centre Rotterdam, the Netherlands.
Background And Objectives: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study.
Methods: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL).
Editor's Choice - Real World Study of Mortality After the Use of Paclitaxel Coated Devices in Peripheral Vascular Intervention.
Eur J Vasc Endovasc Surg
January 2023
Division of Vascular Surgery, University of Vermont Medical Centre, Division of Vascular Surgery, Burlington, USA. Electronic address:
Objective: This observational cohort study examined outcomes after peripheral vascular intervention (PVI) with paclitaxel coated devices (PCD) and non-PCD, and evaluated heterogeneity of treatment effect in populations of interest.
Methods: The study included patients undergoing percutaneous transluminal angioplasty and or stent placement between 1 October 2015 and 31 December 2018 in the Vascular Quality Initiative Registry linked to Medicare claims. It determined differences in patient mortality and ipsilateral major amputation after PVI with PCD and non-PCD using Kaplan-Meier analyses and Cox regressions with inverse probability weighting in three cohorts: (A) patients treated for femoropopliteal or infrapopliteal occlusive disease with or without any other concurrent treatment (n = 11 452); (B) those treated for isolated superficial femoral or popliteal artery disease (n = 5 519); and (C) patients with inclusion criteria designed to approximate RCT populations (n = 2 278).
A Delphi Consensus on Patient Reported Outcomes for Registries and Trials Including Patients with Intermittent Claudication: Recommendations and Reporting Standard.
Eur J Vasc Endovasc Surg
November 2022
Department of Vascular Medicine, Research Group GermanVasc, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Brandenburg Medical School Theodor Fontane, Neuruppin, Germany. Electronic address:
Objective: This study aimed to develop a core set of patient reported outcome quality indicators (QIs) for the treatment of patients with intermittent claudication (IC), that allow a broad international implementation across different vascular registries and within trials.
Methods: A rigorous modified two stage Delphi technique was used to promote consensus building on patient reported outcome QIs among an expert panel consisting of international vascular specialists, patient representatives, and registry members of the VASCUNET and the International Consortium of Vascular Registries. Potential QIs identified through an extensive literature search or additionally proposed by the panel were validated by the experts in a preliminary survey and included for evaluation.
An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort.
Neurology
September 2022
From the Departments of Neurology (S.E.L., S. Arends, B.v.d.B., A.Y.D., P.A.v.D., K.K., L.W.G.L., W.V.R., J.R., C.V., B.C.J.), and Viroscience (A.A.v.d.E.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Neurology (H.A., T.H.), Aarhus University Hospital, Denmark; Department of Neurology (G.A.), Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, University of Rome "Sapienza," Sant' Andrea Hospital, Italy; Department of Neurology (S. Arends), Haga Teaching Hospital, The Hague, the Netherlands; Department of Neurology (S. Attarian), Reference Centre for NMD, CHU Timone, Marseille, France; Department of Neurology (F.A.B.), Instituto de Investigaciones Neurológicas Raúl Carrea, FLENI, Buenos Aires, Argentina; Division of Neurology (K.J.B., E.L.P.), Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa; Department RH-MDC-Immunology (M.R.B., M.M.), Reinier de Graaf Gasthuis, Delft, the Netherlands; Department of Neurology (L.B.), IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Neurology (B.v.d.B., F.H.V.), Franciscus Gasthuis & Vlietland, Schiedam, the Netherlands; Department of Neurology (P.V.d.B.), University Hospital St. Luc, University of Louvain, Brussels, Belgium; Department of Neurology (J.B.), Saarland University Medical School, Homburg (previous hospital), and MVZ Pfalzklinikum (J.B.), Kusel, Germany (current hospital); Department of Neurology (M.B.), Leeds Teaching Hospitals, United Kingdom; Department of Neurology (C.C., V.N.-H.), Neuromuscular Unit, Bellvitge University Hospital-IDIBELL, CIBERER, Barcelona, Spain; Department of Neurology (D.R.C.), Johns Hopkins University, Baltimore, MD; Institute of Infection, Immunity and Inflammation (A.D., H.J.W.), University of Glasgow, United Kingdom; National Hospital Copenhagen (C.D.d.l.C.), Copenhagen, Denmark; Department of Clinical Neurosciences (T.E.F.), University of Calgary, Alberta, Canada; Nuffield Department of Clinical Neurosciences (J.F., S.R.), University of Oxford, John Radcliffe Hospital, United Kingdom; Department of Neurology (T.G.-S., J.P.), Hospital ClÃnico de Santiago, Spain; Neurology, Neuromuscular Diseases, Electromyography (J.M.G.), Hospital for Special Surgery; Weill Medical College of Cornell University (J.M.G.), New York; Department of Neurology (K.C.G., B.S.), Tufts University School of Medicine, Boston, MA; Department of Neurology (V.G.), Montefiore Medical Center, New York; Department of Neurology (R.D.M.H.), King's College Hospital, London, United Kingdom; Department of Neurology (H.-P.H.), University of Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), University of Sydney, Australia; Department of Neurology (H.-P.H.), Medical University of Vienna, Austria; Laboratory of Gut-Brain Signaling (I.H., I.J., Z.I., Q.D.M.), Laboratory Sciences and Services Division, icddr,b, Dhaka, Bangladesh; Department of Neurology (J.V.H., S.H.S.), Odense University Hospital, Denmark; Department of Neurology (J.K.L.H.), The Walton Centre, Liverpool, United Kingdom; Department of Neurology (S. Karafiath), Utah Valley University, Orem; Department of Neurology (H.D.K.), University Health Network, University of Toronto, ON, Canada; Department of Neurology (R.P.K., K.K.), Albert Schweitzer Hospital, Dordrecht, the Netherlands; Department of Neurology (N.K.), University of Vermont Medical Centre, Burlington; Department of Neurology (M.K., S. Kusunoki), Kindai University, Faculty of Medicine, Osaka, Japan; Department of Neurology (L.W.G.L., L.H.V.), St. Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands; Department of Neurology (S. Kuwabara), Chiba University, Japan; Department of Neurology (H.C.L.), University Hospital of Cologne, Germany; Department of Neurology (L.M.-A., L.Q.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Neurology (J.A.L.M.), Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom; Department of Neurology (S.M.), Hospital de PediatrÃa J.P. Garrahan, Buenos Aires, Argentina; Neuromuscular and Neuroimmunology Service (E.N.-O.), IRCCS Humanitas Research Hospital, Milan University, Italy; Department of Clinical Neurophysiology (Y.P.), Reference Centre for NMD, CHU Nantes, France; Department of Neurology (R.R.), Hospital Británico, Buenos Aires, Argentina; Department of Immunology (W.V.R., A.P.T.-G., R.H., B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Neurology (S.R.), Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital; Department of Neurology (R.C.R.), Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge Biomedical Campus, United Kingdom; Department of Medicine (N.S., T.C.-Y.), University of Malaya, Kuala Lumpur; Department of Neurology (S.H.S.), University of Southern Denmark, Odense; Department of Clinical Neurophysiology (H.T.), Aarhus University Hospital, Denmark; and Hospital Universitario Marques de Valdecilla (M.J.S.T.), Santander, Cantabria, Spain.
Background And Objectives: Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale.
Methods: We analyzed the first 1,000 patients included in the International GBS Outcome Study with available biosamples (n = 768) for the presence of a recent infection with , hepatitis E virus, , cytomegalovirus, and Epstein-Barr virus.
Electrodiagnostic subtyping in Guillain-Barré syndrome: Use of criteria in practice based on a survey study in IGOS.
J Peripher Nerv Syst
September 2022
Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Electrodiagnostic (EDx) studies are helpful in diagnosing and subtyping of Guillain-Barré syndrome (GBS). Published criteria for differentiation into GBS subtypes focus on cutoff values, but other items receive less attention, although they may influence EDx subtyping: (a) extensiveness of EDx testing, (b) nerve-specific considerations, (c) distal compound muscle action potential (CMAP)-amplitude requirements, (d) criteria for conduction block and temporal dispersion. The aims of this study were to investigate how these aspects were approached by neuromuscular EDx experts in practice and how this was done in previously published EDx criteria for GBS.
View Article and Find Full Text PDFElectrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values.
Clin Neurophysiol
June 2022
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Objective: To describe the heterogeneity of electrodiagnostic (EDx) studies in Guillain-Barré syndrome (GBS) patients collected as part of the International GBS Outcome Study (IGOS).
Methods: Prospectively collected clinical and EDx data were available in 957 IGOS patients from 115 centers. Only the first EDx study was included in the current analysis.
Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
Neurology
February 2022
From the Departments of Neurology (A.Y.D., C.W., B.v.d.B., C.V., J.R., S.E.L., K.K., B.C.J.), Public Health (H.F.L.), and Immunology (B.C.J.), Erasmus MC, University Medical Centre Rotterdam; Department of Neurology (C.W., J.P.A.S.), Maasstad Hospital, Rotterdam, the Netherlands; Laboratory of Gut-Brain Signaling (B.I., N.P., Z.I.), Laboratory Sciences and Services Division, Dhaka, Bangladesh; Department of Neurology (A.D., G. Chavada, H.J.W.), College of Medical, Veterinary and Life Sciences, University of Glasgow, UK; Department of Neurology (Y.Y., S. Kusunoki), Kindai University Faculty of Medicine, Osaka-Sayama City, Osaka, Japan; Department of Neurology (M.M.D.), University of Kansas Medical Center, Kansas City; Department of Neurology (W.W., N.K.), University of Vermont Medical Centre, Burlington; National Institute of Neurosciences and Hospital (Q.D.M.), Agargoan, Bangladesh; Department of Neurology (T.H.), Aarhus University Hospital; Department of Neurology (S.H.S.), Odense University Hospital and University of Southern Denmark, Odense, Denmark; Department of Neurology, Neuromuscular Unit (C.C.), Bellvitge University Hospital-IDIBELL, CIBERER, Barcelona, Spain; Department of Neurology (K.B.), Groote Schuur Hospital, University of Cape Town, South Africa; Department of Neurology (J.A.L.M.), Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; Department of Neurology (B.v.d.B., C.J.G.), Franciscus Vlietland Hospital, Schiedam, the Netherlands; Department of Neurology (L.B.), IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Neurology (S. Kuwabara), Chiba University, Japan; Department of Neurology (P.V.d.B.), Neuromuscular Reference Centre, University Hospital Saint-Luc, University of Louvain, Brussels, Belgium; Department of Neurology (S.M.), Hospital de PediatrÃa J.P. Garrahan, Buenos Aires, Argentina; Dysimmune Neuropathies Unit, Department of Systems Medicine (G.A.M.), Tor Vergata University Hospital, Rome, Italy; Department of Medicine (N.S.), University of Malaya, Kuala Lumpur; Department of Neurology (G.G.), University Hospital of Modena, Italy; Department of Clinical Neurophysiology, Reference Centre for NMD (Y.P.), CHU Nantes, France; Department of Neurology (J.B.), Saarland University Medical School, Homburg-Saarland (previous affiliation); MVZ Pfalzklinikum (J.B.), Kusel, Germany (current affiliation); Department of Neurology (K.K., R.P.K.), Albert Schweitzer Hospital, Dordrecht, the Netherlands; Department of Neurology (C.M.), Hospital Británico, Buenos Aires, Argentina; Department of Neurology (M.J.S.T.), Hospital Marques de Valdecilla, Santander; Department of Neurology (L.Q., I.I.), Hospital de la Santa Creu i Santa Pau, U.A.B. CIBERER and ERN-NMD, Barcelona, Spain; Department of Neurology (Y.W.), Affiliated Hospital of Jining Medical University, Shandong Province, China; Neuromuscular and Neuroimmunology Service (E.N.-O.), IRCCS Humanitas Clinical and Research Institute, Milan University, Rozzano, Italy; Nuffield Department of Clinical Neurosciences (S.R.), University of Oxford and Oxford University Hospitals NHS Foundation Trust, UK; Department of Neurosciences, Ophthalmology, Rehabilitation, Genetics and Maternal Sciences (A.S.), University of Genova; IRCCS San Martino Hospital (A.S.), Genova, Italy; Department of Neurology (J.P.), Hospital ClÃnico de Santiago, Santiago de Compostela (A Coruña), Spain; Department of Neurology (F.H.V.), Franciscus Vlietland Hospital (location: Franciscus Gasthuis), Rotterdam, the Netherlands; Department of Neurology (H.C.L.), University Hospital of Cologne, Germany; Department of Neurology (V.G.), Montefiore Medical Centre, Bronx, NY; Department of Neurology (G. Cavaletti), University Milano-Bicocca, Monza, Italy; Department of Neurology (G.G.-G.), Hospital Universitario Infanta SofÃa, San Sebastián de los Reyes, Spain; Department of Neurology (F.A.B.), Instituto de Investigaciones Neurológicas Raúl Carrea, Buenos Aires, Argentina; Department of Neurology (L.H.V.), St. Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands; Department of Neurology (H.D.K.), University Health Network, University of Toronto, Canada; Department of Neurology (E.D.), University Hospital of Larissa, Greece; Department of Neurology, Reference Centre for NMD (S.A.), CHU Timone, Marseille, France; Department of Neurology (A.J.v.d.K., F.E.), Amsterdam University Medical Centre, University of Amsterdam, Neuroscience Institute, Netherlands Neuromuscular Centre, Euro-NMD; Department of Neurology (P.W.W.), Haga Hospital, Den Haag; Department of Neurology (H.J.G.), Reinier de Graaf Hospital, Delft, the Netherlands; Department of Neurology (R.D.M.H.), King's College Hospital, London; Department of Neurology (J.K.L.H.), The Walton Centre, Liverpool, UK; Department of Neurology (K.A.S.), University of Texas Health Science Centre at Houston; Department of Neurology (S. Karafiath), University of Utah School of Medicine, Salt Lake City; Department of Neurology (M.V.), Lahey Hospital and Medical Center, Tufts University School of Medicine, Burlington, MA; Department of Neurology (G.A.), Mental Health and Sensory Organs (NESMOS), University of Rome "Sapienza," Sant'Andrea Hospital, Rome, Italy; Department of Clinical Neurosciences (T.E.F.), University of Calgary, Canada; Department of Neurology (C.G.F.), Maastricht University Medical Centre, the Netherlands; Department of Neurology (M.B.), Leeds Teaching Hospitals; Department of Neurology (R.C.R.), Addenbrooke's Hospital, Cambridge, UK; Department of Neurology (N.J.S.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY; Department of Neurology (R.F.), Scientific Institute San Raffaele, Milan, Italy; Department of Neurology (G.W.v.D.), Canisius Wilhelmina Hospital, Nijmegen; Department of Neurology (M.P.J.G.), Jeroen Bosch Hospital, 's-Hertogenbosch; Department of Neurology (C.S.M.S.), Leiden University Medical Centre, the Netherlands; and Department of Neurology (K.C.G.), St. Elizabeth's Medical Centre, Tufts University, School of Medicine, Boston, MA.
Article Synopsis
- The study looked at a score called mEGOS that helps predict if people with a sickness called Guillain-Barré syndrome (GBS) will be able to walk on their own or not.
- Researchers used information from 1,500 patients from a big study to see if mEGOS worked well for people from different regions and made some improvements to it.
- The updated score showed good results in different areas, but some places had better or worse outcomes than expected, and they found that things like age and how weak someone’s limbs were were important for predicting problems.
Editor's Choice - International Variations and Sex Disparities in the Treatment of Peripheral Arterial Occlusive Disease: A Report from VASCUNET and the International Consortium of Vascular Registries.
Eur J Vasc Endovasc Surg
December 2020
Division of Vascular Surgery, University of Vermont Medical Centre, Burlington, VT, USA.
Objective: The aim of this study was to determine sex specific differences in the invasive treatment of symptomatic peripheral arterial occlusive disease (PAOD) between member states participating in the VASCUNET and International Consortium of Vascular Registries.
Methods: Data on open surgical revascularisation and peripheral vascular intervention (PVI) of symptomatic PAOD from 2010 to 2017 were collected from population based administrative and registry data from 11 countries. Differences in age, sex, indication, and invasive treatment modality were analysed.
Fungal ball of the maxillary sinus and the risk of persistent sinus dysfunction after simple antrostomy.
Am J Otolaryngol
November 2020
Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia; Rhinology and Skull Base Research Group, Applied Medical Research Centre, University of New South Wales, Sydney, Australia.
Background: Maxillary sinus fungal ball is a common cause of unilateral maxillary sinusitis. Fungal balls or mycetomas are primarily treated with surgery to remove the fungus. However, this assumes the pre-fungal ball sinus cavity was normal and post-surgery patients may suffer from mucostasis in the sinus cavity with persistent symptoms.
View Article and Find Full Text PDFEditor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
Eur J Vasc Endovasc Surg
April 2020
Department of Vascular Medicine, Research Group GermanVasc, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Objective: The aim of this study was to determine the survival of patients after use of paclitaxel coated devices (PCX), as a recent meta-analysis of randomised trials reported higher mortality in patients treated with PCX balloons and stents METHODS: A retrospective health insurance claims analysis of patients covered by the second largest insurance fund in Germany, BARMER, was used to identify index femoropopliteal arterial interventions between 1 January 2010 and 31 December 2018. To ensure first PCX exposure, patients with prior deployment of PCX were excluded. The study cohort was stratified into patients with chronic limb threatening ischaemia (CLTI) and intermittent claudication (IC), then into balloons vs.
View Article and Find Full Text PDFQuality Indicators in Peripheral Arterial Occlusive Disease Treatment: A Systematic Review.
Eur J Vasc Endovasc Surg
November 2019
Department of Vascular Medicine, Working Group GermanVasc, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. Electronic address:
Objectives: This systematic review aimed to identify evidence based quality indicators for invasive revascularisation of symptomatic peripheral arterial occlusive disease (PAOD).
Methods: A systematic search of clinical practice guidelines, consensus statements, systematic reviews, and meta-analyses reporting quality indicators in patients undergoing invasive open and percutaneous revascularisations for symptomatic PAOD (PROSPERO registration number: CRD42019116317) was performed. Furthermore, a grey literature search was conducted involving databases of professional vascular medical organisations.
Epidemiology of potential drug-drug interactions in elderly population admitted to critical care units of Peshawar, Pakistan.
BMC Pharmacol Toxicol
December 2018
Department of Pharmacy, University of Malakand, Lower Dir District, Pakistan.
Background: Aging population, is a reality in many countries because of improvement in the health care, patient safety and other supplemental factors. Pharmacotherapy in this population must be evaluated due to their higher susceptibility to adverse drug outcomes, like potential drug-drug interactions (PDDIs). Research in this regard is limited particularly in developing countries.
View Article and Find Full Text PDFWATER II (80-150 mL) procedural outcomes.
BJU Int
January 2019
University of Montreal Hospital Centre, University of Montréal, Montreal, QC, Canada.
Objectives: To present early safety and feasibility data from a multicentre prospective study (WATER II) of aquablation in the treatment of symptomatic men with large-volume benign prostatic hyperplasia (BPH).
Methods: Between September and December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volume of 80-150 mL underwent aquablation in a prospective multicentre international clinical trial. Baseline demographics and standardized postoperative management variables were carefully recorded in a central independently monitored database.
Functional Impairment and Risk of Venous Thrombosis in Older Adults.
J Am Geriatr Soc
September 2017
Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, Netherlands.
Objectives: To determine the role of age-specific risk factors for thrombosis in older age, such as functional impairment.
Design: Case-control study.
Setting: The Age and Thrombosis-Acquired and Genetic risk factors in the Elderly Study, a two-center study conducted in the Netherlands and the United States from 2008 to 2011.
Clinical features of venous insufficiency and the risk of venous thrombosis in older people.
Br J Haematol
November 2015
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Venous thrombosis is common in older age, with an incidence of 0·5-1% per year in those aged >70 years. Stasis of blood flow is an important contributor to the development of thrombosis and may be due to venous insufficiency in the legs. The risk of thrombosis associated with clinical features of venous insufficiency, i.
View Article and Find Full Text PDF